European Psychiatry
June 1, 2026
E. Lo, A. K. C. Chau, A. E. Z. Lian et al.
Introduction Robust evidence supports the co-occurrence of dissociation and psychosis and their subclinical manifestations in both clinical and non-clinical populations. However, it remains unclear whether specific dissociative symptoms are uniquely associated with individual psychotic symptoms, particularly within the positive dimension. The network theory of psychopathology offers a useful...
European Psychiatry
June 1, 2026
S. Wong, V. Tsang, Brendan Tao et al.
Introduction Positive feedback from a mental health treatment program that uses treatment adjuncts inspired researchers to assess the potential role of the Apollo Neuro device in mental health outcomes. Objectives To assess the impact of the Apollo Neuro device on anxiety levels in a ketamine-assisted therapy treatment program, comparing those using the device with those not using the device....
European Psychiatry
June 1, 2026
Ágnes Zinner-Gérecz, X. Gonda, Szilvia Kresznerits
Introduction Endometriosis is a chronic, systemic, estrogen-dependent gynecological disorder affecting approximately 10% of women of reproductive age. Beyond the hallmark physical symptoms, the condition is associated with significant psychological burden. The disease not only generates local inflammation but also affects central pain modulation and gene expression in brain regions responsible...
European Psychiatry
June 1, 2026
W. Aldulaimy, A. Shah
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...
European Psychiatry
June 1, 2026
J. B. French, J. Kar, B. R. Carr
Introduction The psychiatric incorporation of mindfulness has advanced without a parallel precision in definition. Within both clinical and lay discourse, mindfulness is often conflated with meditation broadly, or with forms of contemplation oriented toward ethical or spiritual ends. This conceptual slippage obscures distinct phenomenological structures and risks importing unexamined...
European Psychiatry
June 1, 2026
T. Sagues, A. Barnes, C. Fernández et al.
Introduction Intranasal esketamine has emerged as an innovative option for the management of treatment-resistant depression (TRD), offering a novel mechanism of action and rapid antidepressant effects. However, evidence regarding the clinical trajectory after treatment discontinuation remains limited, raising questions about the durability of its therapeutic benefits and the optimal maintenance...
European Psychiatry
June 1, 2026
J. Marta, Â. Ferreira, C. Batista et al.
Introduction Treatment-Resistant Depression (TRD) is a major clinical challenge, affecting about 30% of patients with major depressive disorder. It is associated with high morbidity and mortality, reflected in increased suicide risk, hospitalizations, and impaired quality of life. Electroconvulsive Therapy (ECT) remains the therapeutic gold standard, particularly in severe cases with psychotic...
European Psychiatry
June 1, 2026
Nawfel Ayad, Samer Makhoul, F. Alkhaja
Introduction Treatment-resistant depression remains a major clinical challenge, with many patients experiencing relapse despite advances in medication and psychotherapy. Esketamine offers rapid relief from depressive symptoms, while psychotherapy helps patients build lasting skills to manage their condition. Despite their individual effectiveness, little is known about how these treatments work...
European Psychiatry
June 1, 2026
Nawfel Ayad, Samer Makhoul
Introduction Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce Objectives This study aimed to evaluate the long-term effectiveness and tolerability of...
European Psychiatry
June 1, 2026
Sofia von Humboldt, Isabel Leal
Introduction Meditation may serve as a protective factor for mental well-being in older adults, helping them cope with the ongoing challenges of chronic illness. Objectives The objectives are to: 1) explore the emotional experiences of meditation among older adults living with chronic diseases, and 2) examine the impact of meditation on their mental health. Methods The study involved 426...
European Psychiatry
June 1, 2026
A. M. Matas Ochoa, A. R. Quiroga, I. D. Sacristán
Introduction Psychedelics are hallucinogenic agents that are awakening scientific interest in recent years, especially in the field of mental health. Psychedelics induce non-ordinary states of consciousness and alterations in the emotions and in cognition and could be beneficial in treating some mental illness. Objectives The objective of the poster is to expand knowledge about emerging...
European Psychiatry
June 1, 2026
A. Rami
Introduction Suicidal crisis represents a major psychiatric emergency, often occurring in the context of mood disorders and requiring rapid, effective interventions. Traditional antidepressant treatments usually have a delayed onset of action, underscoring the need for fast-acting therapeutic alternatives. In recent years, ketamine—an NMDA receptor antagonist—has emerged as a promising option...
European Psychiatry
June 1, 2026
V. Mitikhin, L. Alieva, T. Solokhina
Introduction The presence of occupational stress among medical workers in psychiatric facilities is a factor that can negatively affect not only their quality of life and well-being, but also the quality of medical care provided to patients (Solokhina T. et al., 2024). Considering the results obtained (Oshevsky D. et al., 2025), it is relevant to develop and implement technologies aimed at...
European Psychiatry
June 1, 2026
V. Martiadis, Fabiola Raffone, Serena Testa et al.
Introduction Treatment-resistant depression (TRD) is a severe condition associated with high suicide risk and limited response to conventional antidepressants. Intranasal esketamine has shown rapid efficacy in reducing depressive symptoms and suicidal ideation. Objectives This observational study assessed the real-world effectiveness of esketamine in reducing suicidal ideation, self-harm...
European Psychiatry
June 1, 2026
O. Płaza, Robert Madejek, M. M. Dutsch-Wicherek et al.
Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...
European Psychiatry
June 1, 2026
N. Aguayo-Verdugo, N. Ulloa-Chamblás, R. Zúñiga-Tapia et al.
Introduction University students, particularly in health-related fields, face rising levels of stress, anxiety, and depression, which negatively affect academic performance, social engagement, and overall well-being. Post-pandemic challenges, such as social isolation, uncertainty, and abrupt transitions to online learning, have exacerbated these issues. Mindfulness-based interventions (MBIs)...
European Psychiatry
June 1, 2026
A. Kuzma-Hunt, Z. Hamadeh, V. Tsang
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
European Psychiatry
June 1, 2026
M. P. Rapagnani, L. Veronesi, F. Sartini
Introduction In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments of antidepressants. Esketamine (the S-enantiomer of ketamine) nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonine-norepinephrine reuptake inhibitor (SNRI), is the only treatment approved in Europe...
European Psychiatry
June 1, 2026
E. D. Cindik-Herbrueggen, A. S. Kucukali
Introduction Adult attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with mood and anxiety disorders (Sandstrom et al. Acta Psychiatr Scand 2021;143 380–391), and when major depressive disorder (MDD) is present, it often follows a treatment-resistant course (Thapar et al. J Child Psychol Psychiatry 2023;64 4–15). Intranasal esketamine, a non-competitive NMDA-receptor...
European Psychiatry
June 1, 2026
O. Rashid
Introduction In India’s context of an unregulated drug supply, psychosis is often attributed to cannabis based on patient history alone. However, the widespread contamination of substances with synthetic cannabinoids, opioids, and novel psychoactive substances (NPS) precipitates severe and atypical psychotic presentations that are frequently misdiagnosed as Cannabis-Induced Psychosis (CIP)....
European Psychiatry
2026
Andy Lu, Heidi Xu, Gia Han Le et al.
4 citations
The reported mixed findings suggest that the opioid system may exert a partial mediating effect of ketamine in TRD. However, given the inconsistent attenuation of ketamine's antidepressant effects by opioid receptor antagonists, the opioid system likely functions as a context-dependent modulator rather than a primary mediator, particularly at standard antidepressant doses.
European Psychiatry
2026
Shakila Meshkat, Qiaowei Lin, Rachel Sousa-Ho et al.
Abstract Background Psychedelic-assisted psychotherapy has shown potential for psychiatric disorders. However, the magnitude of symptom change in control groups remains poorly understood. We aim to evaluate within-group effects in control groups and compare them to treatment groups in psychedelic trials. Methods A systematic search was conducted up to 1 July 2025. The study protocol was...
European Psychiatry
April 1, 2025
Michel Sabé
3 citations
Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or persistent psychotic symptoms. However, meta-analytic evidence of the precise risk for psychedelic-induced de novo and exacerbation of psychosis in people with pre-existing psychotic disorders is lacking. Objectives We conducted an overview of...
European Psychiatry
April 1, 2025
Albino J Oliveira-Maia
1 citation
Abstract The potential of psychedelic substances to treat mental illness is of significant clinical and societal interest, leading to academic and industry-based research to test their effects. Partly, such research was conducted to fulfil requirements of government agencies such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), that have started defining...
European Psychiatry
April 1, 2025
T. Fernandes, J. G. Freire, M. C. Pais et al.
Introduction Functional neurological disorders (FND), also referred to as conversion disorder or psychogenic neurological disorders, are one of the most common and disabling conditions in the neurology practice field, with very limited treatment options. FNDs present with sensory and/or motor symptoms that can mimic other neurological conditions, but appear to be related to recognizable...